Pharma News, 2023

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...

Pharmaceuticals firm Lupin Ltd on Friday said it will fully acquire French pharmaceutical company Medisol for 18 million euros (over Rs 160 crore). 

The FDA granted breakthrough therapy designation to Boehringer Ingelheim’s Spevigo (spesolimab) as a treatment to prevent flares in adults with generalized pustular psoriasis (GPP). ...

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for KALYDECO (ivacaftor) to treat children with cystic fibrosis (CF) aged between one and four months. ...

The Food and Drug Administration approved a first-of-its-kind RSV vaccine by pharmaceutical company GlaxoSmithKline for older adults on Wednesday, in time to help the U.S. combat RSV infections and...

The FDA has placed a partial clinical hold on Sun Pharma’s IND application for Deuruxolitinib (CTP-543), which was being studied in patients with alopecia areata, an autoimmune disease that inclu...

Merck also intends to forge partnerships in the field of bio-research with major Korean universities.

An experimental Alzheimer’s drug developed by Eli Lilly and Co slowed cognitive decline by 35 percent in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a sec...

Sanofi has signed an exclusive worldwide licensing agreement with Maze Therapeutics for its glycogen synthase 1 (GYS1) programme, including a lead candidate for Pompe disease and other glycogen sto...